Form 4: Arcutis Biotherapeutics Director Howard G. Welgus Reports Stock Transactions
SEC Form 4 Filing
Director Howard G. Welgus reports exercising stock options and selling shares of Arcutis Biotherapeutics, Inc. on July 1, 2024.
Summary
- On July 1, 2024, Howard G. Welgus, a director of Arcutis Biotherapeutics, Inc., executed transactions involving the company's common stock.
- Welgus exercised stock options to acquire 5,681 shares and 4,319 shares at a price of $1.6806 per share.
- Simultaneously, Welgus sold 10,000 shares at $9.3141 per share.
- Following these transactions, Welgus directly owns 180,339 shares and indirectly owns 24,991 shares through The Welgus Living Trust.
- The transactions were executed under a pre-arranged 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports stock transactions by a director. The transactions themselves don't inherently indicate a positive or negative outlook for the company.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It doesn't necessarily reflect the overall health or prospects of Arcutis Biotherapeutics but offers insight into one director's transactions.
Key Dates
| Date | Description |
|---|---|
| 03/13/2029 | Expiration date of stock options |
| 07/01/2024 | Date of stock option exercise and stock sale |
| 07/02/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.